The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
In a move reflecting confidence in technology and medical growth strategies, analyst reports recommend retaining Gartner and Glaukos shares within investment portfolios. Gartner's robust stock performance is primarily supported by its AI-enhanced research platforms and aggressive share repurchase programs that enhance shareholder value. Meanwhile, Glaukos is benefiting from the growth of its iDose TR product and the launch of Epioxa, although reports indicate that competition risks and reimbursement challenges in the healthcare sector remain persistent.
These recommendations come as technology and healthcare stocks show divergent performance; while Gartner (IT) focuses on AI integration, investors are monitoring peers like Forrester Research. Per market data, the corporate trend toward share buybacks remains a key driver for stock prices amid current market volatility. Additionally, the medical device sector sees Glaukos competing with majors like Alcon, making new innovations like Epioxa critical for maintaining market share.
Sign in to access this content
Sign InTraders should watch price levels for Gartner (IT) which closed at $452.10 and Glaukos (GKOS) at $118.45 (close June 5, 2026). Regarding forward catalysts, the market awaits Fed Chair Powell's speech on May 31, 2026, which could impact risk appetite in growth sectors, alongside the U.S. ISM Manufacturing PMI data scheduled for release on June 1, 2026.